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Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by abnormal
accumulation of β-amyloid and tau and synapse dysfunction in memory-related
neural circuits. Pathological and functional changes in the medial temporal lobe, a
region essential for explicit memory encoding, contribute to cognitive decline in AD.
Surprisingly, functional imaging studies show increased activity of the hippocampus
and associated cortical regions during memory tasks in presymptomatic and early
AD stages, whereas brain activity declines as the disease progresses. These findings
suggest an emerging scenario where early pathogenic events might increase neuronal
excitability leading to enhanced brain activity before clinical manifestations of the
disease, a stage that is followed by decreased brain activity as neurodegeneration
progresses. The mechanisms linking pathology with synaptic excitability and plasticity
changes leading to memory loss in AD remain largely unclear. Recent studies
suggest that increased brain activity parallels enhanced expression of genes involved
in synaptic transmission and plasticity in preclinical stages, whereas expression of
synaptic and activity-dependent genes are reduced by the onset of pathological and
cognitive symptoms. Here, we review recent evidences indicating a relationship between
transcriptional deregulation of synaptic genes and neuronal activity and memory loss in
AD andmouse models. These findings provide the basis for potential clinical applications
of memory-related transcriptional programs and their regulatory mechanisms as novel
biomarkers and therapeutic targets to restore brain function in AD and other cognitive
disorders.
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Introduction
The rise of life expectancy has profoundly increased the aging population, and hence the
prevalence of age-related cognitive disorders, including Alzheimer’s disease (AD). AD is a
devastating neurological disorder characterized by early episodic memory deﬁcits that progresses
with cognitive impairments and neuropsychiatric symptoms and ﬁnally ends with general disabling
dementia. The disease is preceded by a presymptomatic or preclinical stage that can last for years
during which the clinical symptoms do not manifest but the pathological process starts (Sperling
et al., 2014). In a subsequent prodromal stage namedmild cognitive impairment (MCI), the disease
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is characterized by impairment of memory (amnesia) and other
cognitive functions. The majority of subjects with MCI, which
represent 10–20% of population older than 65 years, suﬀer from
the disease in the following years (Petersen, 2011).
Memory decline is accompanied by pathological features in
the brain of AD patients, including accumulation of extracellular
amyloid plaques composed of β-amyloid (Aβ) peptides and
intracellular neuroﬁbrillary tangles (NFTs) formed by aggregated
hyperphosphorylated microtubule-associated protein tau. These
pathological lesions accumulate in brain regions essential for
memory encoding and storage, such as the medial temporal
lobe (MTL) and related cortical areas (Spires-Jones and Hyman,
2014). Tau pathology starts in the entorhinal cortex (EC) and then
spreads to the hippocampal formation and limbic and association
cortices (Braak and Braak, 1991). Progression of NFTs correlates
well with cognitive decline and neuron loss, whereas amyloid
plaques are abundant in neocortical regions but they do not
correlate with the degree of memory loss (Arriagada et al., 1992;
Gomez-Isla et al., 1997).
It is becoming clear that speciﬁc memory circuits are
aﬀected by changes in synaptic function and plasticity during
the course of the disease. Indeed, synapse dysfunction and
loss is an early pathological feature that correlates closely
with cognitive impairment (Terry, 2000; Scheﬀ et al., 2007).
Recent functional imaging studies reveal decreased activity
of the MTL in AD patients, whereas function of cortical
and temporal lobe regions, particularly the hippocampus, are
increased during memory tasks in preclinical and early stages of
the disease (i.e., MCI; for review see Sperling et al., 2010). This
enhancement of brain activity may represent a compensatory
mechanism resulting from reduced neuronal connectivity that
can maintain memory encoding at the beginning of the disease
process. Notably, enhanced neuronal activity parallels increased
expression of genes involved in synaptic transmission and
plasticity at presymptomatic or very early AD stages, whereas
deregulation of synaptic gene programs occurs at early and late
pathological stages. Here, we summarize pathological as well
as functional features occurring in the brain of human and
AD mouse models during aging, and discuss recent evidences
suggesting a relationship between gene expression changes
and neuronal activity and memory disturbances during the
progression of AD.
Hippocampal Pathology and Activity in
AD
Declarative episodic memories of live facts and events depend
on the MTL and connected cortical regions. The MTL includes
the hippocampal formation (CA ﬁelds, dentate gyrus and
subiculum), amygdala and adjacent cortical regions (entorhinal,
perirhinal, and parahippocampal cortices; Squirre and Zola-
Morgan, 1991). The EC receives cortical sensory information and
projects excitatory inputs directly to CA1 pyramidal neurons or
to the dentate gyrus and CA3 hippocampus through the perforant
pathway (Van Hoesen and Pandya, 1975). CA3 neurons project
Schaﬀer collaterals to CA1 pyramidal neurons, which ﬁnally
project to the subiculum and deep EC layers IV, V and VI (EC-IV-
VI; Figure 1). The MTL undergoes atrophy and hypometabolism
not only in AD but also in MCI stages (Press et al., 1989; Mosconi
et al., 2005; La Joie et al., 2013), an eﬀect observed at least
4 years in advance to cognitive symptoms (Tondelli et al., 2012).
Indeed, disruption of the hippocampus, a critical component of
this memory circuit, is suﬃcient to produce anterograde amnesia
(Zola-Morgan et al., 1986).
The EC is severely aﬀected by pathological events and
neurodegeneration early in AD, likely contributing to memory
impairment. AD brains are characterized by a speciﬁc pattern
of degenerating neurons in EC-II/IV layers and subiculum
(Hyman et al., 1984). Cholinergic neurons are particularly
FIGURE 1 | Hippocampal circuitry in the mouse brain. Modified original
drawing of Santiago Ramón y Cajal’s (1911, left) and schematic diagram
(right) of the rodent hippocampal circuitry. The picture shows the flux of
excitatory projections (arrows) from entorhinal cortex (EC) neurons (green)
directly to CA1 (orange) or CA3 (red) hippocampal pyramidal neurons or
indirectly through projections to the dentate gyrus (DG, blue) through the
perforant pathway. DG granule neurons project along the mossy fibers to
CA3 pyramidal neurons. CA3 axons project through the Schaffer collaterals
to CA1 pyramidal neurons, which finally project to the subiculum and deep
EC IV- VI layers.
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vulnerable in AD, and therefore classical therapeutic treatments
are based on acetylcholinesterase inhibition. One of the earliest
pathological features linked to AD progression is accumulation
of NFTs, which occurrs in at least 70% of brains of healthy
individuals at sixties (Nelson et al., 2012). Tau pathology starts
in the EC and continues to CA1/subiculum ﬁeld and amygdala
prior to clinical symptoms (Braak stages I–II; Hyman et al.,
1986; Arriagada et al., 1992). As AD progresses, tau pathology
propagates in a sequential regional fashion to limbic and
association cortices (Braak stages III–VI) apparently through
an aggregation spreading mechanism (Braak and Braak, 1991;
Clavaguera et al., 2013). Indeed, NFTs and amyloid plaques are
abundant in the terminal sites of the EC projections such as
the dentate gyrus (Hyman et al., 1990). Collectively, progressive
accumulation and spreading of pathological hallmarks in the
MTL suggests that disruption of this neural circuit may
contribute to memory decline during the progression of the
disease.
Functional magnetic resonance imaging (fMRI) studies show
decreased activity and connectivity of the hippocampus, and
temporal and prefrontal cortices during episodic memory
tasks in AD patients [(Press et al., 1989; Small et al., 1999;
Sperling et al., 2003; Pariente et al., 2005; Bai et al., 2009),
for review see (Dickerson and Sperling, 2009)]. By contrast,
MCI subjects show abnormal activation of the hippocampus
and EC during face-name, visual object and verbal associative
memory tasks (Dickerson et al., 2005; Hamalainen et al., 2007;
Kircher et al., 2007). Compared with healthy aged controls,
asymptomatic subjects at risk for AD, including presenilin-1
(PSEN1) C410Y and E280A carriers, show higher activation
of the hippocampus and frontal and temporal cortices during
associative memory encoding years before clinical symptoms
(Bassett et al., 2006; Mondadori et al., 2006; Yassa et al.,
2008; Reiman et al., 2012). This increase of brain activity
seems to reﬂect a compensatory mechanism to overcome neural
dysfunction in preclinical stages, a process that may be necessary
for appropriate memory encoding and retrieval (Kircher et al.,
2007; O’Brien et al., 2010; Sperling et al., 2010). Taken together,
these studies demonstrate increased activity of the MTL early
during presymptomatic AD stages followed by decreased activity
as the disease progresses.
Cortical Default Network in AD
Memory encoding and retrieval are aﬀected by interconnected
neocortical regions known as the default mode network, which
is active at wakeful rest and deactivates during memory encoding
(Buckner et al., 2008). The default mode network is connected
to the MTL and includes the medial prefrontal cortex, the
posteromedial cingulate cortex, the adjacent ventral precuneus,
and the medial, lateral and inferior parietal cortices (Kobayashi
and Amaral, 2007).
Speciﬁc regions of the cortical default network are functionally
disrupted in AD and subjects at risk for AD (i.e., MCI;
for a review, see Sperling et al., 2010). Hyperactivation of
parietal and prefrontal cortices during memory encoding is
accompanied by hippocampal hypoactivation in AD patients
(Grady et al., 2003; Pariente et al., 2005). Reduced default network
connectivity at rest, but increased activity during performance
of attentional and associative memory tasks is observed in
MCI and mild AD stages (Koch et al., 2014). Similar to AD
patients, older cognitively normal subjects with brain amyloid
deposition show signiﬁcant reduced connectivity of the default
network to the hippocampus in resting state (Hedden et al.,
2009; Sheline et al., 2010). More striking, asymptomatic subjects
with AD-linked autosomal dominant PSEN1 mutations show
decreased activity of the precuneus/posterior cingulate and
parietal cortex in resting state (Chhatwal et al., 2013), but
increased activity of the frontal, parietal and prefrontal cortex
during memory encoding (Wishart et al., 2006; Reiman et al.,
2012). These results indicate disruption of the default mode
network years before cognitive or behavioral symptoms, which
suggests that early AD-associated pathology exerts deleterious
functional eﬀects on distinct memory circuits prior to memory
impairment.
Effect of Aβ on Hippocampal Activity and
Memory in AD Mouse Models
Mice expressing human β-amyloid precursor protein (APP), TAU
and/or PSEN1 genes harboring familial AD-linked mutations
develop AD pathological hallmarks, neuroinﬂamation and
memory impairments (McGowan et al., 2006). APP and APP/PS1
transgenic mice develop age-dependent amyloid deposits and
memory impairments in the absence of tau inclusions (Hsiao
et al., 1996; Chapman et al., 1999; Koistinaho et al., 2001).
APP transgenic mice show spatial and contextual memory
impairments tightly associated with changes in long-term
potentiation (LTP), a form of synaptic plasticity thought to be
the cellular basis of learning and memory. Tg2576 (Swedish:
APP KM670/671NL), APPSw,Ind (J20) and APP V717I transgenic
mice that develop amyloid plaques display impaired hippocampal
synaptic plasticity and memory deﬁcits (Chapman et al., 1999;
Dewachter et al., 2002; Saura et al., 2005). In APP transgenic
mice, including PDAPP (Indiana: APP V717F), Tg2576, APPLd2
(London: V642I), APP23 (Swedish), APPSw,Ind (J20), APP/PS1
and 3xTg-AD (APP Swedish, Tau P301L, PS1 M146V), altered
hippocampal synaptic plasticity and memory deﬁcits precede
amyloid plaque pathology suggesting that disruption of memory
neural circuits is independent of plaque deposition (Dodart et al.,
1999; Hsia et al., 1999; Koistinaho et al., 2001; Kelly et al.,
2003; Van Dam et al., 2003; Dominguez-del-Toro et al., 2004;
Billings et al., 2005; Saura et al., 2005; Jacobsen et al., 2006;
Gruart et al., 2008). Notably, hippocampal-dependent synaptic
plasticity andmemory deﬁcits in 3xTg-AD, APPSw,Ind and ArcAβ
transgenic mice are associated with the presence of intraneuronal
Aβ accumulation, which precedes amyloid plaques (Billings et al.,
2005; España et al., 2010a).
It has been recently postulated that synaptic excitability
changes may alter memory networks leading to cognitive
disturbances in AD (Santos et al., 2010, for review). APPSw,Ind
(J20) mice show prior to amyloid plaque deposition enhanced
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synaptic plasticity in the Schaﬀer collateral pathway coinciding
with early hippocampal-dependent memory deﬁcits (Saura et al.,
2005). During aging, APPSw,Ind mice develop associative memory
deﬁcits accompanied by amyloid plaque accumulation and
LTP impairments in the hippocampus (Figure 2). Similarly,
young free-plaque TgCRND8 and 3xTg-ADmice show increased
synaptic plasticity caused by enhancement of synaptic excitability
in the hippocampus, a phenotype associated with episodic
memory impairments (Jolas et al., 2002; Davis et al., 2014).
Several studies have also shown increased neuronal hyperactivity
and excitability in the cortex of young APP transgenic
mice before or when the ﬁrst amyloid plaques appear
(Palop et al., 2007; Busche et al., 2008; Minkeviciene et al.,
2009; Gurevicius et al., 2013). This increased excitability
is likely responsible for spontaneous epileptic seizures and
premature death of APP mice (Palop et al., 2007; Minkeviciene
et al., 2009). Enhancement of neuronal activity associated
with early pathological and memory changes in AD mouse
FIGURE 2 | Age-dependent pathological, synaptic plasticity and
associative memory changes in APP transgenic mice. (A) Brain
sections of 3–6 months-old APPSw,Ind (J20) transgenic mice (APP) stained
with an anti-Aβ antibody revealing the presence of amyloid plaques in the
hippocampus at 6 months. (B) Contextual associative memory in one-shock
contextual fear conditioning task. Three and six month-old APP mice exhibit
significantly reduced levels of freezing at 24 h indicating disruption of
long-term associative memory. Data represent the mean ± SEM. ∗P < 0.05,
∗∗P < 0.0001. (C), Time course of LTP induction at the CA1 Schaffer
collaterals after theta burst stimulation (TBS) in 3- and 6-months old
non-transgenic (control) and APP mice (n = 5–7). Notice the differential LTP
in APP mice at 3 months (up) and 6 months (down) compared to the
respective non-transgenic (control) mice. fEPSP, field excitatory postsynaptic
potentials. Images are adapted from Saura et al. (2005).
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models resembles the clinical symptoms of MCI subjects (see
above).
The mechanism by which Aβ induces neuronal
hyperexcitability is mediated by an increase of spontaneous
action potential ﬁring likely due to an impairment of inhibitory
interneuron activity and/or increase of presynaptic vesicle
release (Palop et al., 2007; Minkeviciene et al., 2009; Fogel
et al., 2014). In this regard, hyperactivity of CA1 hippocampal
neurons caused by loss of somatostatin inhibitory interneurons
results in memory disturbances in APP transgenic mice
(Perez-Cruz et al., 2011). By contrast, increasing the inhibitory
activity of parvalbumin interneurons by restoring the voltage-
gated sodium channel subunit Nav1.1 improves memory in
APPSw,Ind mice (Verret et al., 2012). Finally, Aβ contributes to
emotional psychiatric disturbances by disrupting glutamatergic
excitatory/GABAergic inhibitory neurotransmission in the
basolateral amygdala (España et al., 2010a). Based on
these results, it is plausible that early Aβ accumulation
aﬀects the inhibitory/excitatory neuronal balance of speciﬁc
memory-related neural circuits. This will result in increased
neuronal excitability leading to excitotoxicity and synapse and
neuronal loss at later pathological stages, when plaque load,
synaptic plasticity deﬁcits and memory loss are prominent
(Figure 3).
Synapse Dysfunction in AD
Synapse dysfunction is a common pathological feature of several
dementing disorders being the major correlate of cognitive
impairment in AD (Terry et al., 1991). Synapse loss aﬀects
diﬀerent neuronal populations and neurotransmitter systems
in brains of AD subjects (Masliah et al., 1990; Scheﬀ et al.,
1990, 2007). Individuals with amnestic MCI and AD have
signiﬁcantly fewer synapses and synaptic proteins in CA1
hippocampus and inferior temporal and posterior cingulate
gyrus (Scheﬀ et al., 2007). Accumulation of soluble toxic
forms of tau and Aβ at synapses may be a crucial event
leading to synapse loss and neurodegeneration (Spires-Jones
and Hyman, 2014). Thus, loss of dendritic spines in cortical
pyramidal neurons parallels tau phosphorylation during aging
(Merino-Serrais et al., 2013), whereas soluble Aβ peptides and
oligomers induce synapse loss in mice, rats and non-human
primates (Forny-Germano et al., 2014). In APP transgenic,
synapse loss and morphology changes are common features
that precede amyloid deposition (Lanz et al., 2003; Wu et al.,
2004; Rutten et al., 2005; Jacobsen et al., 2006; Wilke et al.,
2014). Interestingly, reduced spine density in hippocampal
neurons is associated with synaptic plasticity andmemory deﬁcits
in Tg2576 mice (Jacobsen et al., 2006; Rocher et al., 2008;
D’Amelio et al., 2011; Perez-Cruz et al., 2011; Ricobaraza et al.,
2012).
The molecular mechanisms leading to synapse dysfunction
and loss in AD are largely unclear. Aβ oligomers impair
glutamatergic neurotransmission in an activity-dependent
manner (Lacor et al., 2004; Deshpande et al., 2009) and
cause synapse loss by postsynaptic mechanisms involving
deregulation, removal and/or mistargeting of extrasynaptic
NMDA and synaptic α-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid (AMPA) glutamate receptors (Shankar
et al., 2007; D’Amelio et al., 2011; Miñano-Molina et al.,
2011). For instance, reduced phosphorylated and surface
expression of GluA1 is associated with early spatial memory
deﬁcits in APP transgenic mice (Miñano-Molina et al.,
2011). Pharmacological treatments that inhibit aberrant
extrasynaptic NMDA receptors or activate cAMP/PKA/CREB
signaling reverse Aβ-induced dendritic spine loss and
memory deﬁcits (Smith et al., 2009; Talantova et al.,
2013).
On the other hand, both Aβ and APP modulate excitatory
presynaptic vesicle release in an activity-dependent manner
(Abramov et al., 2009; Fogel et al., 2014), whereas neuronal
activity modulates generation and deposition of Aβ in vivo
(Bero et al., 2011), suggesting that neuronal hyperactivity can
contribute to Aβ generation and accumulation. Taken together,
these results point toward a bidirectional regulation between
Aβ and neuronal activity through presynaptic and postsynaptic
mechanisms.
FIGURE 3 | Hypothetical model linking expression of synaptic genes
and neuronal and memory network activities during AD
progression. In healthy state, gene transcription controls expression of
synaptic genes to maintain neuronal activity and synaptic plasticity in
active memory circuits. In prodromal and very early AD stages,
pathological changes increase expression of synaptic genes contributing
to inhibitory/excitatory imbalance resulting in enhancement of synaptic
excitability and plasticity in memory circuits. At intermediate and severe
AD stages, sustained neuronal dysfunction causes transcriptional
deregulation of synaptic genes resulting in synapse dysfunction and
plasticity impairments, which contributes to memory network disruption
and neurodegeneration.
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Differential Brain Gene Expression in
Presymptomatic and Pathological AD
Stages
Cognitive decline is associated with changes of gene expression
in the brain during aging and AD. Transcriptome proﬁle
studies indicate that genes related to synaptic function, energy
metabolism and protein synthesis are downregulated in the brain
during aging, while expression of inﬂammatory genes increases
especially in the sixth to seventh decades of life (Berchtold et al.,
2008; Cribbs et al., 2012; Kumar et al., 2013). Transcription
of genes associated with neuron loss, glial activation and lipid
metabolism increases with aging while inﬂammatory cytokines
and microglial genes are activated early in AD (Podtelezhnikov
et al., 2011), which corroborates an early inﬂammatory response
in AD (Parachikova et al., 2007). Systems biology analysis
identiﬁed two relevant pathways related to mitochondrial/energy
metabolism and synaptic plasticity conserved between AD and
aging (Miller et al., 2008). Interestingly, APP and tau transcripts
are upregulated and regulators of APP metabolism (BACE1,
PSEN1, PSEN2) and tau phosphorylation (MARK1/3/4, CDK5,
PINK1) are downregulated in memory-related brain regions in
individuals with moderate and clinical diagnosis of AD (Liang
et al., 2010).
Altered expression of genes related to synapse, energy
metabolism and transcriptional regulation processes exacerbate
in the brain during the progression of AD pathology contributing
likely to cognitive dysfunction (Yao et al., 2003; Blalock et al.,
2004; Liang et al., 2008; Miller et al., 2008; Tan et al., 2010; Silva
et al., 2012; Berchtold et al., 2013). Remarkably, downregulation
of synaptic gene transcripts in CA1 hippocampal neurons of
MCI/AD brains correlates with pathological cognitive status
(Ginsberg et al., 2012; Counts et al., 2014). By contrast,
genes changes related to metabolic/mitochondrial function
occur in neurons and astrocytes in AD brain (Liang et al.,
2008, 2010; Sekar et al., 2015). In astrocytes, deregulation of
genes associated with cytoskeleton, proliferation, apoptosis, and
ubiquitin-mediated degradation occur at early Braak stages, while
deregulation of intracellular signaling pathways (PI3K/Akt, MAP,
insulin) are associated with late pathological stages (Simpson
et al., 2011).
Microarrays comparison analysis of synaptic genes in control
and AD brains at diﬀerent ages (20–99 years) revealed signiﬁcant
expression changes in genes regulating vesicle traﬃcking/release,
neurotransmitter receptors, postsynaptic density, cell adhesion
and neuromodulation in normal aging and AD, suggesting
that similar synaptic genes are vulnerable to aging and AD
(Berchtold et al., 2013). Indeed, expression of genes associated
with synaptic signaling and structure, protein biosynthesis and
mitochondrial/energy metabolism is predominantly increased
in the hippocampus, EC and/or temporal gyrus in MCI and
decline in AD (Berchtold et al., 2014). Genes that regulate
vesicle and synapse function, including those encoding diﬀerent
isoforms of synaptophysin (SYP), SNAP25, synapsin (SYN),
synaptogyrin (SYNGR1), synaptobrevin (VAMP), synaptotagmin
(SYT), syntaxin-1 (STX1), synaptopodin (SYNPO) and PSD-95
are downregulated in the hippocampus and EC at moderate
and severe AD stages (Liang et al., 2010; Ginsberg et al., 2012;
Counts et al., 2014). Indeed, altered expression of genes related
to synapse function and plasticity correlates better with AD
pathology and clinical severity (Gomez Ravetti et al., 2010;
Berchtold et al., 2014). Table 1 summarizes changes of expression
of some synaptic genes in AD brain and mouse models. It should
be noticed that transcript changes in AD brain could reﬂect
the loss of neurons and synapses in advanced disease stages,
a possibility not generally considered in the majority of these
studies.
In the prefrontal cortex, transcriptome changes aﬀecting
cell signaling, metabolic, inﬂammation and neurotransmission
pathways occur at early pathological stages coinciding with
the presence of intraneuronal Aβ (Bossers et al., 2010). Two
patterns of gene regulation can be detected: (1) genes related
to synaptic function, ATP synthesis and RNA increase in early
pathological stages (Braak 0–III) and decline later (Braak IV–
VI), and (2) genes related to cell diﬀerentiation/proliferation,
metal ion binding, antigen processing and transcriptional
regulation decrease early and then increase in late Braak
stages (Bossers et al., 2010). Synaptic genes upregulated
at early pathological stages include potassium voltage-gated
channels (KCNS3, KCNB1, KCNA1, and KCNAB1), GABA
receptors (GABRA1, GABRD, GABRG2), vesicle exocitosis
(SNAP25, CPLX1, VAMP7, SYT1, SYT3, SYT4, NAPB, and
SV2C) and vesicle endocytosis (clathrin, CLTC, PACSIN1)
proteins.
These above ﬁndings indicate a close relationship between
transcriptional deregulation and AD-associated neuropathology
in memory-related neural circuits. We therefore hypothesize
that increased expression of synaptic genes resulting from
excitatory/inhibitory imbalance can enhance neural excitability
and circuit activity during pre-symptomatic and very early
disease stages of AD. In turn, this leads to global gene
deregulation, synaptic dysfunction and degeneration and
memory loss during the progression of the disease (Figure 3).
Synaptic Gene Expression Changes in
AD Mouse Models
Transcriptome proﬁle studies in AD mouse models have
revealed altered expression of genes related to mitochondrial
function, metabolism, insulin signaling, calcium homeostasis,
inﬂammation, and synaptic plasticity during AD-like
pathological progression (see Table 1, for synaptic genes).
3xTg-AD mice shows early hippocampal deregulation of
genes linked to mitochondrial morphology and function,
neuroinﬂammation, calcium homeostasis, neurotransmission,
neuronal loss, and cell cycle (Gatta et al., 2014). 3xTg-AD
mice show age-dependent expression changes on AMPA
receptor subunits, with marked reduction of Gria2 and
Gria3 in the hippocampus at 12 months. Interestingly,
levels of Gria2, Gria3, and Gria4 transcripts are increased
in the hippocampus of young 3xTg-AD animals suggesting
a compensatory mechanism against AD-related synaptic
dysfunction (Cantanelli et al., 2014). Several synaptic plasticity
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TABLE 1 | Summary of expression of synaptic genes in AD and mouse models.
Gene Gene name Function Model Region Levels References
ARC Activity-regulated
cytoskeleton-associated
protein
Synapse structure AD
APPSw,Ind
APP/PS1
Tg2576/APPL
Hip
Hip
Hip/Cx
Hip
Down
Down
Down
Up
Ginsberg et al. (2012), Palop et al. (2005),
España et al. (2010a), Parra-Damas et al.
(2014), Dickey et al. (2003), Perez-Cruz
et al. (2011)
CHGA ChromograninA Vesicle
trafficking/release
AD
AD
APPSw,Ind
Hip
CSF
Hip
Down
Down
Down
Marksteiner et al. (2002), Simonsen et al.
(2008), Perrin et al. (2011)
Parra-Damas et al. (2014)
GRIA GluA1
GluA2,3,4
Synaptic transmission BraakII-IV/
AD
APPSw,Ind,APPTg
AD/3xTg-AD
Hip, EC, MTG
Hip/Cx
Hip/Cx
Hip
Down
Down
Down
Up/Down
Liang et al. (2010), Wakabayashi et al.
(1999), Ginsberg et al. (2012),
Parra-Damas et al. (2014), Dickey et al.
(2003), Cantanelli et al. (2014)
NEFL Neurofilament Neuron structure FTD, AD
APPSw,Ind
APP/PS1
CSF
Hip
Hip/Cx
Up
Down
Down
Sjögren et al. (2000)
Parra-Damas et al. (2014)
Dickey et al. (2003)
NRN1 Neuritin Neurite APPSw,Ind Hip Down Parra-Damas et al. (2014)
NRX1 Neurexin 1 Synapse structure MCI
AD
EC, SFG
Hip, EC
Up
Down
Berchtold et al. (2014)
NR4A1/2 Nuclear receptor sub 4,
1/2
Synaptic plasticity AD
APPSw,Ind,APPTg
Hip
Hip/Cx
Down
Down
Dickey et al. (2003), Chu et al. (2006)
España et al. (2010b), Parra-Damas et al.
(2014)
RAB RAB2,5,7 Vesicle trafficking MCI/AD
APPSw,Ind
Hip
Hip
Up
Down
Ginsberg et al. (2010)
Parra-Damas et al. (2014)
SCG2 Secretogranin II Neurotransmission AD
APPSw,Ind
Hip
Hip
Down
Down
Marksteiner et al. (2002)
Parra-Damas et al. (2014)
SNAP25 Synaptosomal-associated
protein 25kDa
Vesicle trafficking MCI
AD
3xTg-AD
EC, Hip, PC
EC, Hip, MTG
Hip
Up
Down
Up/Down
Berchtold et al. (2014), Bossers et al.
(2010), Liang et al. (2010)
Gatta et al. (2014)
STX Syntaxin1A
Syntaxin4A
Syntaxin 6
Syntaxin 18
Vesicle
trafficking/release
MCI/AD
AD/APPSw,Ind
MCI
AD
AD
APPSw,Ind
Hip, MTG, EC
Hip
Hip, PCG
Hip
Hip, MTG, PC
Hip
Down
Down
Up
Down
Down
Down
Counts et al. (2014), Liang et al. (2010)
Ginsberg et al. (2012), Parra-Damas et al.
(2014), Berchtold et al. (2014)
Liang et al. (2010)
Parra-Damas et al. (2014)
SYT SYT1,3,4
SYT6
SYT1,3,5,6,11,12
SYT4
Vesicle trafficking/
release
BraakII/III
MCI
AD
BraakII/IV
APPSw,Ind
PC
Hip, PCG
Hip, EC, PC
Hip, EC, MTG
Hip
Up
Up
Down
Down
Down
Bossers et al. (2010)
Berchtold et al. (2014)
Ginsberg et al. (2012), Liu et al. (2006)
Liang et al. (2010)
Parra-Damas et al. (2014)
VAMP VAMP1,2,4
VAMP1,2,3,4
Vesicle trafficking MCI
AD
Hip, PCG
Hip, EC, PC
Up/Down
Down
Berchtold et al. (2013, 2014), Counts
et al. (2014), Liang et al. (2010)
AD, Alzheimer’s disease; FTD, frontotemporal dementia; MCI, mild cognitive impairment; EC, entorhinal cortex; Hip, hippocampus; MTG, middle temporal gyrus;
PC, prefrontal cortex; PCG, post temporal gyrus; SFG, superior frontal gyrus.
genes, including Arc, early growth response 1 (Egr1), NR2B,
Gria1, Homer-1 and Nr4a1/Nur77, are signiﬁcantly reduced
in the hippocampus of 18 months-old APP/PS1 transgenic
mice coinciding with amyloid plaques and memory deﬁcits
(Dickey et al., 2003). Interestingly, expression of genes directly
implicated in learning/memory and plasticity is increased in
the hippocampus of environmental enriched APP/PS1 (Lazarov
et al., 2005).
Recently, comparison of diﬀerent lines of APP and tau
transgenic mice revealed that elevation of immune system genes
is associated with appearance of amyloid plaques, whereas
reduced expression of synaptic genes and increased cell death
genes correlate with cortical and hippocampal tau pathology
(Matarin et al., 2015). This result agrees with previous reports
showing reduced expression of genes related to glutamatergic
(Arc, Gria1, Gria2, Grik4, Psd95), or GABAergic (Gad67,
Gabarap-11) neurotransmission and vesicle traﬃcking (Syn3,
Syb, Synj, Snap29, Syp, Stx4a, Stx7) in hTau mice (Alldred
et al., 2012), and elevation of inﬂammatory genes in brain
regions containing amyloid deposits in APP mice (Dickey
et al., 2003; Landel et al., 2014). In summary, transcriptome
analysis demonstrates deregulation of common cellular pathways
in several AD transgenic mouse models during AD-associated
pathology.
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Activity-Dependent Gene Expression and
Memory Deficits in AD Mouse Models
Activity-dependent gene expression is a fundamental mechanism
mediating structural changes at synapses during memory
formation. Cognitive deﬁcits in human and mice are associated
with dysregulation of activity-dependent genes and transcription
factors (West and Greenberg, 2011). Downregulation of activity-
dependent genes involved in synaptic plasticity and memory,
including the activity-regulated cytoskeleton-associated protein
(Arc), c-fos and Bdnf, are associated with learning and memory
deﬁcits in AD and APP transgenic mice (Phillips et al., 1991;
Dewachter et al., 2009; España et al., 2010b). Notably, ARC
transcripts are signiﬁcantly reduced at early and advanced AD
pathological stages (Ginsberg et al., 2012; Parra-Damas et al.,
2014). Similarly, Arc expression is markedly decreased in the
hippocampus and visual cortex of APP transgenic mice after
experience and memory training (Palop et al., 2005; Rudinskiy
et al., 2012; Parra-Damas et al., 2014). Paradoxicaly, Arc is
increased in individual cortical neurons close to amyloid plaques
and CA1 pyramidal neurons in APP mice, an eﬀect attributed to
neuronal hyperactivity caused by decreased synaptic inhibition
(Perez-Cruz et al., 2011; Rudinskiy et al., 2012). Despite the
established disruption of activity-dependent gene expression in
AD, the regulatory transcriptional mechanisms underlying gene
changes causing memory loss in this disease are largely unknown.
Understanding these mechanisms may oﬀer new opportunities
for therapeutic intervention in cognitive disorders.
To discern transcriptional mechanisms related to memory
impairment in AD, we recently performed genome-wide
transcriptome analyses in naïve and memory trained non-
transgenic and APPSw,Ind (J9) mice. Gene-annotation analysis
revealed a gene cluster of 164 transcripts deregulated in the
hippocampus of 6 months-old APPSw,Ind mice compared to
non-transgenic mice after memory training. The biological
pathways associated with these genes are learning/memory,
neurotransmission, synaptic plasticity, glutamatergic and
GABAergic neurotransmission, oxidative phosphorylation
and AD (Parra-Damas et al., 2014). Coinciding with initial
intraneuronal Aβ accumulation and memory deﬁcits, APPSw,Ind
mice show deregulation of a transcriptional program dependent
on the cAMP-response element binding protein (CREB)-
regulated transcription coactivator-1 (CRTC1), which includes
genes involved in neurotransmission (Scg2, Syt4, Stx4, Stx18,
Rab2a, Gria1, Chga), synaptic plasticity/memory (Arc, c-
fos, Nr4a1, Nr4a2, Bdnf ) and neuritogenesis (Nefl, Nrn1)
(Parra-Damas et al., 2014) (Table 1). This result is consistent
with a decline of synaptic gene transcripts coinciding with the
presence of intraneuronal Aβ and preceding synapse loss in
human prefrontal cortex at intermediate pathological stages
(Bossers et al., 2010).
Genetic and pharmacological studies have shown that
disruption of CREB signaling mediates synaptic plasticity
and memory impairments in AD (Saura and Valero, 2011).
Accordingly, CREB activation ameliorates synaptic and memory
deﬁcits in APP transgenic mice (Smith et al., 2009; Yiu
et al., 2011), whereas CRTC1 gene therapy reverses early
transcriptional changes and memory impairments in AD
mice (Parra-Damas et al., 2014). In summary, disruption of
CREB/CRTC1-dependent transcription underlies early memory
deﬁcits whereas its activation ameliorates AD-related synaptic
and memory impairments, which provides evidence that
targeting this pathway may be therapeutically beneﬁcial in AD.
Pathogenic and Therapeutic Implications
of Gene Deregulation in AD
AD is the most common form of dementia in the aging
population but, unfortunately, current therapies are not
eﬀective to ameliorate or reverse the clinical symptoms.
Classical pharmacological treatments based on inhibition
of acetylcholinesterase (e.g., donepezil, rivastigmine) or
excitotoxicity (memantine) slow the disease progression but do
not prevent or stop the neurodegeneration process. Alternatively,
anti-amyloid immunotherapy treatments that eﬃciently reduce
amyloid plaque burden fail to improve cognitive performance in
mild-to moderate AD patients (Doody et al., 2014; Salloway et al.,
2014). The discouraging failures of anti-amyloid clinical trials
have raised doubts about the contribution of Aβ as the initiating
factor in AD pathophysiology (Herrup, 2015). Alternatively,
several molecular, genetic and cellular events aﬀected by aging,
the main risk factor of the disease, may contribute to neuronal
dysfunction and degeneration leading to dementia in AD.
In this context, deregulation of genes involved in pathological
pathways, including oxidative stress, mitochondrial/energy
metabolism, synapse dysfunction and inﬂammation, may
be crucial in the etiology of AD. Thus, despite massive
gene expression changes in the brain, few vulnerable
biological pathways, including energy metabolism, synaptic
function/plasticity and inﬂammation are generally altered in
normal aging and AD (Berchtold et al., 2008, 2013; Cribbs
et al., 2012). Gene expression deregulation occurs already
in presymptomatic or early diseases phases (Bossers et al.,
2010; Liang et al., 2010; Berchtold et al., 2014). Thus, synaptic
and energy metabolism gene clusters are upregulated early
during the disease process declining later at intermediate/severe
pathological stages. Based on these results, we hypothesize that
upregulation of synaptic genes contributes to increased neural
excitability and memory circuit activity at presymptomatic
or very early disease stages, which could then trigger gene
deregulation, synaptic dysfunction, degeneration and memory
loss during the progression of the disease (Figure 3). Indeed,
changes in expression of synaptic genes parallel altered activity
of memory circuits indicating a close relationship between
neuropathology, transcriptional deregulation and activity of
susceptible memory circuits in AD (Figure 4).
How changes of synaptic gene programs contribute to
neuronal activity and connectivity alterations leading to memory
loss in cognitive disorders is starting to be elucidated. One
suggested possibility is that Aβ enhances intrinsic neuronal
excitability leading to memory network changes and clinical
manifestations of AD (Palop et al., 2007). Therapeutic approaches
aimed at reducing neuronal hyperactivity may be beneﬁcial to
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FIGURE 4 | Temporal progression of pathological and
transcriptional changes in aging and AD. The diagram represents
the hypothetical temporal progression of memory deficits, expression
of synaptic genes, medial temporal lobe (MTL) activity and Aβ
pathology during aging and AD. Enhanced brain activity at prodromal
AD stages is associated with increased expression of synaptic genes,
whereas decreased brain activity parallels reduction of synaptic genes
as the disease progresses.
stabilize synaptic function and improve cognitive abilities at early
disease stages. In support of this idea, a recent clinical trial
indicates that levetiracetam, an antiepileptic drug that reduces
hippocampal hyperactivity, improves cognition in amnestic
MCI subjects (Bakker et al., 2012). Levetiracetam treatment
also reverses synaptic gene changes as well as functional
abnormalities and cognitive deﬁcits in APP transgenic mice
(Sanchez et al., 2012), whereas decreasing oxidative stress,
excitotoxicity and hyperexcitability without interfering with
amyloid or tau pathologies prevents AD-related memory deﬁcits
(Isopi et al., 2014). Likewise, the antiepileptic drug valproate
ameliorates memory deﬁcits and neuropsychiatric symptoms in
APP transgenic mice (España et al., 2010a; Yao et al., 2014),
but fails to slow cognitive decline and behavioral symptoms at
late diseases stages (Fleisher et al., 2011). The eﬃcacy of anti-
hyperactivity drugs for treating AD will ultimately depend on the
drug type, dosage and disease stage.
Gene proﬁling and transcriptional regulatory mechanisms
involved in memory loss could oﬀer clinical applications as
diagnostic tools, novel biomarkers and therapeutic targets in
AD. First, it is conceivable that meta-analysis of transcriptomic
data from large population-based cohorts of sporadic AD
patients may reveal diﬀerentially altered pathways related
to speciﬁc pathogenic mechanisms, opening new venues to
design personalized therapeutic strategies. Second, individual or
particular set of genes altered in AD brain could be applied as
novel early biomarkers to predict the progression of the disease
and to monitor therapeutic eﬀects in personalized medicine.
Of relevance, synaptic genes identiﬁed by wide-genome proﬁle
analysis in mouse models are deregulated in AD brain or
biological ﬂuids (Table 1). Several of these synaptic proteins,
such as BDNF, secretogranin II, synaptotagmin, chromogranin
A and SNAP25, have been proposed as novel biomarkers for
AD (Simonsen et al., 2008; Li et al., 2009; Perrin et al., 2011;
Brinkmalm et al., 2014). Since testing brain tissue could be of
limited application in population-based screenings, the use of
CSF and blood samples may represent a valuable non-invasive
tool for biomarker analysis. Indeed, deregulation of genes and
microRNAs (miRNAs) in CSF and/or blood (plasma and blood
cells) occurs in AD patients (Chen et al., 2011; Bekris et al.,
2013; Roed et al., 2013), and a gene signature in blood related
to inﬂammation, transcription and cell death was recently used
for diagnosis and prediction of MCI to AD conversion (Roed
et al., 2013). Interestingly, the abundant changes of transcripts of
genes related to synaptic plasticity/transmission, neuritogenesis
and neurological diseases (AD, Parkinsons’disease, and mental
retardation) in blood cells of AD patients suggest a strong
link between blood and brain transcriptional proﬁles in AD
(Naughton et al., 2015). Future identiﬁcation of relevant
biomarkers in biological ﬂuids may be useful for early and
accurate diagnosis of AD.
An important point is that gene expression is regulated by
multiple mechanisms including transcription, translation and
posttranscriptional or posttranslational mechanisms. Among
these, epigenetic regulation has been the intense focus of
research in neurodegenerative diseases in recent years. Epigenetic
chromatin remodeling and DNA modiﬁcations regulate gene
expression during memory formation, whereas epigenetic
dysregulation is associated with aging and cognitive disorders
(Graﬀ and Mansuy, 2009). Thus, global reduction of DNA
methylation and hydroxymethylation occur in the hippocampus
of AD patients at early pathological stages (Chouliaras et al.,
2013; Sanchez-Mut et al., 2013; De Jager et al., 2014). Other
epigenetic factors such as non-coding RNA, in particular miRNAs
and long non-coding RNAs, have also received increasing
attention in neurodegenerative diseases due to their role in
modulating gene expression. A set of miRNAs and long non-
coding RNAs are deregulated in brain, blood, and CSF of AD
patients (Dorval et al., 2013; Lau et al., 2013), which raises
the possibility that non-coding RNAs may play a key role in
gene expression deregulation during the course of the disease.
Nonetheless, speciﬁc miRNAs and long non-coding RNAs aﬀect
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expression of genes involved in AD pathology including gene
regulating APP processing, tau, inﬂammation and apoptosis
(Goodall et al., 2013). The diversity of miRNAs and their
potential to target gene expression of multiple pathways oﬀer
alternative applications of these molecules as novel biomarkers
and therapeutic targets for AD and other neurodegenerative
diseases.
Based on the above studies, epigenetic therapeutic approaches
have been applied in AD mouse models. As an example, histone
deacetylase inhibition increases expression of plasticity genes and
ameliorates synaptic pathology and cognitive deﬁcits in APP
transgenic mice (Ricobaraza et al., 2012). Long-term systemic
treatment with epigenetic drugs may, however, cause broad and
deleterious eﬀects on brain function. Alternatively, targeting
molecules or pathways regulating speciﬁc gene expression
programs in vulnerable memory circuits may represent potential
therapeutic targets for AD. Interestingly, a recent report
demonstrates that a gene therapy approach targeting CRTC1 to
enhance expression of speciﬁc synaptic genes prevents memory
impairments in an AD mouse model (Parra-Damas et al.,
2014). A future scientiﬁc challenge will be the identiﬁcation of
transcriptome signatures in the brain or biological ﬂuids for
early diagnosis and prediction of the disease. In parallel, a better
understanding of the expression regulatory mechanisms of genes
involved in synaptic dysfunction and neurodegeneration will be
crucial to develop eﬃcient therapeutic treatments for AD and
other cognitive disorders.
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